Evidence map›Paper›PMID 34200955›Full record

ArticleInternational journal of molecular sciences2021

Chimeric Stimuli-Responsive Liposomes as Nanocarriers for the Delivery of the Anti-Glioma Agent TRAM-34.

Nikolaos Naziris, Natassa Pippa, Evangelia Sereti, Varvara Chrysostomou, Marta Kędzierska, Jakub Kajdanek, Maksim Ionov, Katarzyna Miłowska, Łucja Balcerzak, Stefano Garofalo and 5 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Liposomal Nanomaterials: A Rising Star in Glioma Treatment.International journal of nanomedicine · 2024
    Review
  6. Article
  7. Review
  8. Polymer-Lipid Hybrid Materials.Chemical reviews · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Nikolaos NazirisSection of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimioupolis Zografou, 15771 Athens, Greece.ORCID 0000-0002-8155-3875
Natassa PippaSection of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimioupolis Zografou, 15771 Athens, Greece.
Evangelia SeretiDepartment of Pharmacology, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.
Varvara ChrysostomouTheoretical and Physical Chemistry Institute, National Hellenic Research Foundation, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece.
Marta KędzierskaDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Jakub KajdanekDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Maksim IonovDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.ORCID 0000-0001-7227-6864
Katarzyna MiłowskaDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Łucja BalcerzakLaboratory of Microscopic Imaging and Specialized Biological Techniques, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland.
Stefano GarofaloDepartment of Physiology and Pharmacology, Laboratory Affiliated to Istituto Pasteur Italia, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Cristina LimatolaDepartment of Physiology and Pharmacology, Laboratory Affiliated to Istituto Pasteur Italia, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0001-7504-8197
Stergios PispasTheoretical and Physical Chemistry Institute, National Hellenic Research Foundation, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece.ORCID 0000-0002-5347-7430
Konstantinos DimasDepartment of Pharmacology, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece.ORCID 0000-0001-7481-9148
Maria BryszewskaDepartment of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.ORCID 0000-0003-4676-3743
Costas DemetzosSection of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimioupolis Zografou, 15771 Athens, Greece.
University of Łódź · PLNational and Kapodistrian University of Athens · GRNational Hellenic Research Foundation · GRUniversity of Thessaly · GRIstituto Neurologico Mediterraneo · ITIstituto Pasteur · IT

Funding

General Secretariat for Research and Technology Τ3ΕΡΑ-00057Hellenic Foundation for Research and Innovation 392Italian Ministry of Health ERP-2016-23671157 - ERP-2016-ENMII-NANOGLIONarodowa Agencja Wymiany Akademickiej 003/P/PROM
6 · The paper itself

Abstract

Nanocarriers are delivery platforms of drugs, peptides, nucleic acids and other therapeutic molecules that are indicated for severe human diseases. Gliomas are the most frequent type of brain tumor, with glioblastoma being the most common and malignant type. The current state of glioma treatment requires innovative approaches that will lead to efficient and safe therapies. Advanced nanosystems and stimuli-responsive materials are available and well-studied technologies that may contribute to this effort. The present study deals with the development of functional chimeric nanocarriers composed of a phospholipid and a diblock copolymer, for the incorporation, delivery and pH-responsive release of the antiglioma agent TRAM-34 inside glioblastoma cells. Nanocarrier analysis included light scattering, protein incubation and electron microscopy, and fluorescence anisotropy and thermal analysis techniques were also applied. Biological assays were carried out in order to evaluate the nanocarrier nanotoxicity in vitro and in vivo, as well as to evaluate antiglioma activity. The nanosystems were able to successfully manifest functional properties under pH conditions, and their biocompatibility and cellular internalization were also evident. The chimeric nanoplatforms presented herein have shown promise for biomedical applications so far and should be further studied in terms of their ability to deliver TRAM-34 and other therapeutic molecules to glioblastoma cells.

Indexed as

Drug Delivery SystemsApoptosisCell ProliferationDrug CarriersGliomaHumansHydrogen-Ion ConcentrationLiposomesNanoparticlesPolymersPyrazolesTumor Cells, CulturedDrug CarriersLiposomesPolymersPyrazolesTRAM 34chimeric liposomesdrug deliveryfunctionalglioblastomapH-responsiveTRAM-34

Identifiers

PMID34200955
PMCPMC8230631
OpenAlexW3167369033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.